Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma?

Expert Opin Biol Ther. 2019 Nov;19(11):1107-1110. doi: 10.1080/14712598.2019.1651288. Epub 2019 Aug 6.

Authors

Alessandra Raimondi¹, Pierangela Sepe¹, Melanie Claps¹, Elena Verzoni¹, Giuseppe Procopio¹

Affiliation

¹ Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy.

PMID: 31369337
DOI: 10.1080/14712598.2019.1651288

No abstract available

Keywords: Biomarker; PD-L1; immunotherapy; metastases; renal cell carcinoma; tumor mutational burden.